The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; none of the 26 sources its claims cite is checked for support yet.
Tadalafil pharmacokinetics in healthy subjects
Open accessAbstract
Aims: To characterize tadalafil plasma pharmacokinetics in healthy subjects following single and multiple doses. Methods: Noncompartmental parameters were calculated for healthy subjects receiving a single 2.5–20‐mg tadalafil dose in 13 clinical pharmacology studies. An integrated statistical analysis of results in 237 subjects provided global averages and an assessment of effects of body mass index (BMI), age, gender and smoking status. Diurnal variation, food effects and proportionality of exposure to dose were analysed in three studies. Multiple‐dose pharmacokinetics were evaluated in a separate study in which parallel groups of 15 subjects received 10 or 20 mg tadalafil once daily for 10 days. Results: Tadalafil was absorbed rapidly with mean Cmax (378 µg l−1 for 20 mg) observed at 2 h; thereafter, concentrations declined nearly monoexponentially with a mean (5th, 95th percentiles) t1/2 of 17.5 (11.5, 29.6) hours. Mean oral clearance (CL/F) was 2.48 (1.35, 4.35) l h−1 and apparent volume of distribution (Vz/F) was 62.6 (39.5, 92.1) l. No clinically meaningful effect of BMI, age, gender or smoking was identified. Exposure was not substantially affected by time of dosing. Food had negligible effects on bioavailability as assessed by 90% confidence intervals for Cmax and AUC mean ratios. Parameters were proportional to dose, indicating that doubling the dose doubled exposure. Steady state was attained by day 5 following once‐daily administration, and accumulation (1.6‐fold) was consistent with the t 1/2. Conclusions: Tadalafil pharmacokinetics are linear with respect to dose and time, and are not affected by food. Systemic clearance is low relative to other phosphodiesterase 5 inhibitors.
Overview
CoChat Summary
TL;DR
Tadalafil pharmacokinetics in healthy subjects are linear with respect to dose and time, with low oral clearance and a prolonged half-life. Food has negligible effect, and once-daily dosing reaches steady state by day 5 with approximately 1.6-fold accumulation.
Key findings
- After a single 20-mg dose, mean Cmax was 378 µg l⁻¹ at median tmax 2 h; mean t₁/₂ was 17.5 h (5th, 95th percentiles 11.5, 29.6), CL/F was 2.48 l h⁻¹ (1.35, 4.35), and Vz/F was 62.6 l (39.5, 92.1).
- Exposure was proportional to dose: doubling the dose increased AUC by 1.96-fold (1.90, 2.02), with β = 0.97 (0.93, 1.01); Cmax increased slightly less than proportionally, by 1.84-fold (1.77, 1.91).
- Food had negligible effect: fed/fasted geometric mean ratios were 1.08 (1.02, 1.15) for AUC and 1.16 (1.07, 1.26) for Cmax, within prespecified equivalence limits. Evening/morning ratios were 0.81 (0.73, 0.90) for AUC and 0.79 (0.71, 0.89) for Cmax, suggesting slightly lower evening bioavailability.
- With 10- or 20-mg once-daily dosing, steady state was attained by day 5; accumulation from day 1 to day 10 was approximately 1.6-fold, and day 10 t₁/₂, CL/F, and Vz/F were similar to single-dose values.
Methods
- Noncompartmental pharmacokinetic parameters were calculated from 13 single-dose clinical pharmacology studies in healthy subjects; an integrated statistical analysis included 237 subjects (186 males), with 45 subjects contributing data from two dosing occasions, and assessed BMI, age, gender, and smoking status.
- Three studies evaluated diurnal effects (12 subjects, 10 mg), definitive food effects (18 subjects, 20 mg fed vs fasted), and dose proportionality (16 subjects, single 2.5-, 5-, 10-, and 20-mg doses in a four-period crossover).
- A separate multiple-dose study randomized 65 healthy subjects to 10 or 20 mg tadalafil once daily for 10 days; 30 subjects participated in the pharmacokinetic assessment. Plasma tadalafil was measured by validated HPLC-MS/MS, and analyses used mixed-effects models, a power model for dose proportionality, and prespecified equivalence confidence intervals.
Limitations
- The paper states that absolute bioavailability of tadalafil following oral dosing has not been determined in any clinical study.
- The paper states that the report does not address populations with erectile dysfunction, hypertension, diabetes, renal insufficiency, hepatic impairment, or CYP3A inducer/inhibitor drug interactions.
- Evident from the text: the integrated analysis was in healthy volunteers who were predominantly Caucasian (228/237) and male (186/237), and several substudies were small (diurnal n = 12; food effect n = 18; dose proportionality n = 16), which limits generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 16 Not checked · 44 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Age, gender and smoking status were also significant covariates; the magnitude of effects is summarized in Table 4.”
§ Tadalafil pharmacokinetics in healthy subjects > Integrated statistical analysis
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no significant difference between t max values.”
§ Tadalafil pharmacokinetics in healthy subjects > Food effect
plainn = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most frequently reported treatment-emergent adverse events in the study of once-daily dosing for 10 days were: headache (66% of 65 subjects), back pain (60%), myalgia (43%) dyspepsia (19%), nausea (19%), dizziness (17%), fatigue (12%), eye pain (11%) and spontaneous penile erection (11%).”
§ Tadalafil pharmacokinetics in healthy subjects > Safety and tolerability
plainn = 65- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Inspection of the distribution of individual dose-normalized AUC values suggested that exposure was proportional to dose across the eightfold range (2.5-20 mg) (Figure 1).”
- Also stated in: § Dose proportionality · boosted
“Proportionality was concluded since the 95% CI for the slope [ β = 0.97 (0.93, 1.01)] for regression of ln(AUC) on ln(dose) was completely contained within the prespecified equivalence interval.”
§ Tadalafil pharmacokinetics in healthy subjects > Dose proportionality
boostedstates an associationn = 16- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Dose proportionality · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mean oral clearance (CL/F) was 2.48 (1.35, 4.35) l h -1”
§ Tadalafil pharmacokinetics in healthy subjects > Abstract
plainn = 237- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
27 more claims
Create a free account to see all 60 claims and every source verdict.
- It may state two separate claims as one. 26
- The quote only partly states this claim. 2
- Probably not a substantial claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, at steady-state concentration, the daily exposure is 1.6-fold greater than the same dose taken intermittently (Forgue et al 2006).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Forgue et al 2006
In the citing paper
“The 17.5 hour half-life of tadalafil lends itself to daily dosing because steady-state plasma concentrations are attained within five days of initiating daily dosing (Forgue et al 2006).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Forgue et al 2006
In the citing paper
“Previous bioequivalence clinical trials reported no differences in tadalafil pharmacokinetics between fed and fasted conditions [44,45].”
From Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride (2023) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Tadalafil pharmacokinetics in healthy subjects > Discussion
“Rate and extent of tadalafil absorption in the morning were slightly lower than in the evening.”
§ Tadalafil pharmacokinetics in healthy subjects > Morning vs. evening administration
“The evening/morning ratio (90% CI) of LS means was 0.81 (0.73, 0.90) for AUC and 0.79 (0.71, 0.89) for C max , suggesting slightly lower bioavailability in the evening.”
Citations
Cites
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,341
Introduction to Linear Regression Analysis.
Assunção, R., Sampson, P. D., Montgomery, D. C., & Peck, E. A. (1993) · Journal of the American Statistical Association · doi:10.2307/2290746 · Cited by 5,389
Nonparametrics: Statistical Methods Based on Ranks.
Beaver, R. J., & Lehmann, E. L. (1976) · Biometrics · doi:10.2307/2529529 · Cited by 2,064
Statistics with Confidence: Confidence Intervals and Statistical Guidelines.
JOLLIFFE, F. R., Gardner, M. J., & Altman, D. G. (1990) · Journal of the Royal Statistical Society Series A (Statistics in Society) · doi:10.2307/2982808 · Cited by 1,319
Lue, T. F. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422407 · Cited by 1,252
Introduction to Linear Regression Analysis
Porter, D. R., Montgomery, D. C., & Peck, E. A. (1993) · Technometrics · doi:10.2307/1269673 · Cited by 974
The log transformation is special
Keene, O. N. (1995) · Statistics in Medicine · doi:10.1002/sim.4780140810 · Cited by 498
Brock, G. B., McMahon, C. G., Chen, K. K., Costigan, T., Shen, W., Watkins, V., Anglin, G., & Whitaker, S. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64442-4 · Cited by 421
Nichols, D. J., Muirhead, G. J., & Harness, J. A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.00027.x · Cited by 358
Confidence Interval Criteria for Assessment of Dose Proportionality
Smith, B. P., Vandenhende, F. R., DeSante, K. A., Farid, N. A., Welch, P. A., Callaghan, J. T., & Forgue, S. T. (2000) · Pharmaceutical Research · doi:10.1023/a:1026451721686 · Cited by 356
Self-citation
Research works printed but not linked: 5
- Ring BJ, 2004, Identification of the human cytochrome P450 (CYP) responsible for the formation of the major oxidative metabolite of tadalafil (Cialis), Drug Metab Rev, 36, 70
- Phillips DL, 2004, Metabolism and excretion of tadalafil in healthy men after oral administration of 100 mg [14C]‐tadalafil, The AAPS J, 6
- Patterson B, 2001, Dose‐normalized pharmacokinetics of tadalafil (IC351) administered as a single dose to healthy volunteers, Int J Impotence Res, 13, S32
- 2002, Guidance for Industry, Food‐Effect Bioavailability and Fed Bioequivalence Studies.
- Angulo J, 2001, IC351 enhances nitric oxide‐mediated relaxation of human arterial and trabecular penile smooth muscle, Diabetologia, 44, A295
Cited by
Items 201–285 of 285
Tienforti, D., Felzani, G., Pasquale, A. B. D., & Barbonetti, A. (2024) · Andrology · doi:10.1111/andr.13642 · Cited by 4
Tadalafil for Treatment of Fetal Growth Restriction: A Review of Experimental and Clinical Studies
Maki, S., Takakura, S., Tsuji, M., Magawa, S., Tamaishi, Y., Nii, M., Kaneda, M. K., Yoshida, K., Toriyabe, K., Kondo, E., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12040804 · Cited by 4
Ölmestig, J. N. E., Mortensen, K. N., Fagerlund, B., Naveed, N., Nordling, M. M., Christensen, H., Iversen, H. K., Poulsen, M. B., Siebner, H. R., & Kruuse, C. R. (2024) · Trials · doi:10.1186/s13063-024-08402-4 · Cited by 4
Tadalafil: Protective Action against the Development of Multiple Organ Failure Syndrome
de Oliveira, G. G., de Oliveira, S. A. H., Botelho, P. H. H., de Oliveira, M. A. B., Bian, K., & Murad, F. (2017) · Brazilian Journal of Cardiovascular Surgery · doi:10.21470/1678-9741-2017-0503 · Cited by 4
Ethans, K. D., Casey, A., Tarhoni, M., Nankar, M., & Entcheva, S. (2018) · Spinal Cord Series and Cases · doi:10.1038/s41394-018-0137-9 · Cited by 4
Srinivas, N. R. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03374.x · Cited by 4
Efficacy of Tadalafil on Ureteral Stent Symptoms: A Randomized Controlled Trial
Haghro, A. F., Hajebrahimi, S., Jabbari, A., Sadeghi, H., & Babaei, H. (2019) · Nephro-Urology Monthly · doi:10.5812/numonthly.85523 · Cited by 4
Acharjya, S. K., Jana, S., Nahak, A., Dash, S. K., Chakraborty, A., & Chowdhury, B. (2022) · Current Pharmaceutical Analysis · doi:10.2174/1573412919666221115123010 · Cited by 3
Ford, J. L., Sabet, A., Natarajan, J., Stieltjes, H., Chao, D. L., Goyal, N., & Csonka, D. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1202 · Cited by 3
Salter, C. A., & Mulhall, J. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816665-9.00006-8 · Cited by 3
Discovery of small molecules for the treatment of Alzheimer’s disease
Rao, P. P. N., Pham, A. T., & Shakeri, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818349-6.00011-x · Cited by 3
Phosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis
Buendía, J. A., Lindarte, E. F., & Patiño, D. G. (2023) · Value in Health Regional Issues · doi:10.1016/j.vhri.2023.02.001 · Cited by 3
Yu, J., Ryu, J. H., Chi, Y. H., Paik, S. H., & Kim, S. K. (2024) · Toxicology in Vitro · doi:10.1016/j.tiv.2024.105922 · Cited by 3
Seftel, A. D., Shinghal, R., Kim, E. D., Samuels, S. M., Ni, X., & Burns, P. R. (2012) · International Journal of Impotence Research · doi:10.1038/ijir.2012.40 · Cited by 3
Pharmacokinetic Characteristics of Bepotastine Besilate in Healthy Subjects
Kim, B., Chung, J., Kim, J.-R., Lim, K. S., Lim, H.-S., Yu, K., Jang, I., & Shin, S. (2007) · Journal of Korean Society for Clinical Pharmacology and Therapeutics · doi:10.12793/jkscpt.2007.15.1.37 · Cited by 3
Avanafil: The Second-Generation Treatment of Erectile Dysfunction
Corona, G., Maggi, M., & Jannini, E. A. (2016) · European Medical Journal · doi:10.33590/emj/10314434 · Cited by 3
Pimentel, H., Wald, M., & NIEDERBERGER, C. S. (2007) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901631 · Cited by 3
Grabowski, T., JAROSZEWSKI, J. J., & Feder, M. (2012) · Medicinal Chemistry Research · doi:10.1007/s00044-012-0187-7 · Cited by 2
Kamel, E. B., Badrawy, M., & Nour, I. M. (2026) · Luminescence · doi:10.1002/bio.70547 · Cited by 2
Treatment of Erectile Disorder
Ismail, E. A., & El‐Sakka, A. I. (2017) · Springer eBooks · doi:10.1007/978-3-319-52539-6_13 · Cited by 2
Miyoshi, T., Hisamitsu, T., Ishibashi‐Ueda, H., Ikemura, K., Ikeda, T., Miyazato, M., Kangawa, K., Watanabe, Y., Nakagawa, O., & Hosoda, H. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.12.013 · Cited by 2
Patient Insight and Treatment Expectations in Erectile Dysfunction
Porst, H. (2016) · European Medical Journal · doi:10.33590/emj/10312334 · Cited by 2
Porat, D., Dukhno, O., Cvijić, S., & Dahan, A. (2024) · The AAPS Journal · doi:10.1208/s12248-024-00985-9 · Cited by 2
Tadalafil for Treatment of Pulmonary Hypertension: Mechanisms, Evidence, and Emerging Perspectives
Elattar, S., Basha, N. R., Salem, A. M., Abdulfattah, A., Taha, S., Frishman, W. H., Aronow, W. S., & Lanier, G. M. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001036 · Cited by 2
Alazizi, A. (2011) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 2
Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction
Myatt, A., & Ian Eardley, C. (2008) · Therapy · doi:10.2217/14750708.5.3.355 · Cited by 2
Tadalafil for the treatment of erectile dysfunction
Carson, C. C. (2003) · Current Urology Reports · doi:10.1007/s11934-003-0026-y · Cited by 2
Phosphodiesterase Inhibitors in the Treatment of Pulmonary Hypertension
Zhao, L., Zhai, Z., Wharton, J., & Wilkins, M. R. (2010) · Springer eBooks · doi:10.1007/978-0-387-87429-6_106 · Cited by 2
Combination therapy for the treatment of lower urinary tract symptoms in men
Barragan-Arteaga, I., & Reyes-Vallejo, L. A. (2016) · Revista Mexicana de Urología · doi:10.1016/j.uromx.2016.05.007 · Cited by 2
Optimum Use of Second Line Treatment Options for Erectile Dysfunction
Arcaniolo, D., Riccardo Autorino, B., Balsamo, R., & SIO, M. D. (2016) · Springer eBooks · doi:10.1007/978-1-4471-4348-2_17 · Cited by 2
Pharmacology of drugs used for the treatment of erectile dysfunction
Ian Eardley, C. (2016) · Wiley eBooks · doi:10.1002/9781118746509.ch6 · Cited by 2
Hussein, M. A., Mosaad, Y. O., & Gobba, N. A. (2018) · Medicinal Chemistry · doi:10.4172/2161-0444.1000505 · Cited by 2
Medical Management of Benign Prostatic Hyperplasia
Showalter, V. C., & Raynor, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-23471-3_3 · Cited by 2
Yıldırım, Ç., Salman, M. Y., Yavuz, A., & Bayar, G. (2022) · Andrologia · doi:10.1111/and.14536 · Cited by 2
Treatment Outcomes of Diabetic Patients With Erectile Dysfunction Prescribed High-Dose Tadalafil
Condina, A., & Lykina, T. (2023) · Cureus · doi:10.7759/cureus.34812 · Cited by 1
Park, S.-J., Gil, M.-C., Lee, B.-S., Jung, M., & Lee, B. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070915 · Cited by 1
Bugs and babies: How gut microbiota affect infertility? A narrative Review
Nabeh, O. A., Menshawey, R., Menshawey, E., & Moubarak, E. S. (2025) · Urologia Journal · doi:10.1177/03915603251358953 · Cited by 1
Desanti, E., Jankowich, M. D., Choudhary, G., Morrison, A., Stanley, Z. K., Garshick, E., Moy, M. L., Kang, M., Wongtrakool, C., Sadikot, R. T., et al. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70167 · Cited by 1
Jose, C., Gharat, S., Baig, A., Pilgaokar, P., & Momin, M. M. (2026) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2026.2675467 · Cited by 1
Faizan, M., & Chauhan, S. (2016) · International Journal of Advanced Research · doi:10.21474/ijar01/932 · Cited by 1
Okour, M., Puri, A., Chen, G., Port, K., Berni, A., Khindri, S. K., Schneider, I., & Tenero, D. M. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.04.007 · Cited by 1
Iqbal, M., Chhiber, S. S., Wazir, B. S., Ramzan, A., & Wani, M. S. (2020) · Indian Journal of Neurosurgery · doi:10.1055/s-0040-1708571 · Cited by 1
Lim, I., Masutani, T., Hashitani, H., Chess‐Williams, R., & Sellers, D. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1175 · Cited by 1
Choc-Tadalafil Fusion: Unlocking Solubility and Taste Harmony with β-CD-Infused Medicated Chocolate
Modi, C. D., Sinha, M., Thakkar, V. T., Rana, H., & Chavda, D. (2024) · Recent Advances in Drug Delivery and Formulation · doi:10.2174/0126673878280254240312053406 · Cited by 1
Wibisono, D. A., Hidayatullah, F., Rizaldi, F., & Djojodimedjo, T. (2023) · Bali Medical Journal · doi:10.15562/bmj.v12i1.4059 · Cited by 1
Moazin, M. S., Baazeem, A., Al-Bakri, A., Dayel, A. A., Amir, A., Sifri, S. A., Reda, M., Bashraheel, F., Alfakhri, A., Hamdy, Y., et al. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2023-0155 · Cited by 1
Trifu, D.-M., Leucuta, D., Pintea-Trifu, M.-L., Elec, F. I., Crişan, N., Eniu, D. T., & Coman, I. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216557 · Cited by 1
Navarrete, R. V., Cardoso, J. V. G., Farre, A. L., Romero, P. Q., & Montero, M. P. (2007) · Actas Urológicas Españolas · doi:10.1016/s0210-4806(07)73623-9 · Cited by 1
Pharmacological Treatment of Pulmonary Hypertension
Takatsuki, S., Eshelman, J., Berg, A. M., & Ivy, D. D. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2464-1_12
Jabbari, A., Hajebrahimi, S., Sadeghi‐Bazargani, H., Farshi, A., & Babaei, H. (2014) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2015/11929
Tadalafil Once-Daily: Patient and Partner Perspective in the Management of Erectile Dysfunction
Gomelsky, A., & Dmochowski, R. R. (2011) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s1570
Gutiérrez-Hernández, P. R., & Rebollo, P. (2014) · Actas Urológicas Españolas (English Edition) · doi:10.1016/j.acuroe.2014.01.004
Gutiérrez-Hernández, P. R., & Rebollo, P. (2013) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2013.11.001
Huerta, L. L. (2015) · Gredos (University of Salamanca) · doi:10.14201/gredos.128169
Novel experimental techniques for biopharmaceutical analysis
Zhou, Z. (2016) · STAX · doi:10.48730/pbyr-j110
Puigvert, A., Prieto, R., & García, F. (2017) · Revista Internacional de Andrología · doi:10.1016/j.androl.2017.02.007
Srinivas, N. R. (2018) · Journal of Bioequivalence & Bioavailability · doi:10.4172/0975-0851.1000e87
Vasodilatadores pulmonares Parte 1
García, C. P. (2013) · Revista Colombiana de Neumología · doi:10.30789/rcneumologia.v25.n2.2013.119
Pham, T., Butler, A., Weideman, R. A., & Annaswamy, T. M. (2021) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000001821
Hatzichristou, D. G. (2014) · Springer eBooks · doi:10.1007/978-3-662-45018-5_5
de Resende, A. A. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2022.tde-12072022-161552
NADCIŚNIENIE PŁUCNE — PATOFIZJOLOGIA I LEKI WYKORZYSTYWANE W TERAPII
Lewandowska, I. L., Zielińska–Pisklak, M., Szeleszczuk, Ł., Pisklak, D. M., & Sobczak, M. (2020) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.17
KUSHWAHA, K. S., PRAKASH, O., Agarwal, N., & Bhaskar, P. (2024) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2024.v17i4.49840
An algorithm of conservative erectile dysfunction treatment
Hradec, T., & Zámečník, L. (2023) · Česká urologie · doi:10.48095/cccu2023007
Adhana, S., Jain, R., Sahoo, S., Thakur, S., Archna, P., Mittal, A., Kundu, B., & Chaudhry, U. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266365593250415101135
Sahoo, B. M., Rao, P. V., Rao, N. S., Lakshmi, K. B., Babu, N. R., Panda, D., & Brahma, C. K. (2025) · Current Spectroscopy and Chromatography · doi:10.2174/0129504910393905250929062420
Stability Study of Tadaflexe (Tadalafil 10 mg) Oral Gel Sachet in Yemeni Honey
Kadi, H. O., & AL-Maktari, A. (2025) · Global Journal of Medical and Clinical Case Reports · doi:10.17352/gjmccr.000228
Kadi, H. O., Kadi, M. H., & Kadi, T. H. (2025) · International Journal of Clinical Virology · doi:10.29328/journal.ijcv.1001066
Ölmestig, J. N. E., Mortensen, K. N., Fagerlund, B., Naveed, N., Nordling, M. M., Christensen, H., Iversen, H. K., Poulsen, M. B., Siebner, H. R., & Kruuse, C. (2024) · Figshare · doi:10.6084/m9.figshare.26944056
Ford, J. H., Ye, W., Ayer, D. W., Mi, X., Bhandari, S., Buse, D. C., & Lipton, R. B. (2024) · Figshare · doi:10.6084/m9.figshare.26580374
Ford, J. H., Ye, W., Ayer, D. W., Mi, X., Bhandari, S., Buse, D. C., & Lipton, R. B. (2024) · Figshare · doi:10.6084/m9.figshare.26580371
Ölmestig, J. N. E., Mortensen, K. N., Fagerlund, B., Naveed, N., Nordling, M. M., Christensen, H., Iversen, H. K., Poulsen, M. B., Siebner, H. R., & Kruuse, C. (2024) · Figshare · doi:10.6084/m9.figshare.26944059
The control of formation and recovery of transverse tubules in the heart
Caldwell, J. L. (2020) · Research Explorer (The University of Manchester)
Eisenmenger Syndrome Hidden by Unrepaired Patent Ductus Arteriosus
Monagle, S. R., Witvrouwen, I., Dhanoa, V., Sathananthan, G., & Grewal, J. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.109079
Fields, E., Elterman, D., Bhojani, N., Polo, J., & Chughtai, B. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2725917
Pharmacological Formulation for ED Management: ODF and ODT
Ragab, M. M., İbiş, M. A., & Aydos, K. (2026) · Springer eBooks · doi:10.1007/978-3-032-29112-7_20
Bai, Y., Chai, W., Guan, M., Chen, X., Georgiadis, J. R., Zhang, X., & Dong, M. (2026) · Andrology · doi:10.1111/andr.70373
Park, S.-H., & Kim, J.-E. (2026) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmag025
Attwa, M. W., Alrabiah, H. K., AlRuqi, O. S., & Kadi, A. A. (2026) · Analytical Methods · doi:10.1039/d6ay01110a
Hofman‐Kotyla, M., Grocholska, P., Wieczorek, R., & Bąchor, R. (2026) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.70188
Lee, Y. S., Chen, C.-S., Lai, G.-S., & Li, J. (2026) · Research Square · doi:10.21203/rs.3.rs-11111288/v1
BindingDB (2020) · UC San Diego · doi:10.7270/q22b91mk
Benign Conditions of the Prostate
Scott, E. T., & Rew, K. T. (2026) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_185-2
Khramov, A. A., Maksimov, M. L., & Zavitkevich, G. I. (2026) · doi:10.33920/med-13-2605-03
Metadata
- Authors
- Forgue, S. T., Patterson, B. E., Bedding, A. W., Payne, C. D., Phillips, D. L., Wrishko, R. E., & Mitchell, M. I.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Forgue, S. Thomas
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2005-12-20
- Volume
- 61
- Issue
- 3
- Pages
- 280-288
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- PMC
- PMC1885023
- OpenAlex
- W1975119053
- Semantic Scholar
- 702568e16e387fed970d136848a9542c93c3e0c0
- Cited by
- 284
- References
- 26
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 20 · 2023: 17 · 2022: 13 · 2021: 14 · 2020: 17 · 2019: 18 · 2018: 14 · 2017: 12 · 2016: 13 · 2015: 11 · 2014: 21 · 2013: 13 · 2012: 11
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- tadalafil, pharmacokinetics, phosphodiesterase-5 inhibitors, oral bioavailability, food effect, dose proportionality, steady-state pharmacokinetics, body mass index, smoking, age and gender effects, healthy volunteers
- MeSH terms
- Tadalafil, Adolescent, Adult, Aged, Biological Availability, Carbolines, Circadian Rhythm, Dose-Response Relationship, Drug, Drug Administration Schedule, Eating, Female, Humans, Male, Metabolic Clearance Rate, Middle Aged, Phosphodiesterase Inhibitors, Body Mass Index, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-14, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-14 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
